Zhu Yuefei, Li Jia, Pang Zhiqing
Department of Biomedical Engineering, Columbia University, New York 10027, USA.
Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China.
Asian J Pharm Sci. 2021 Jan;16(1):4-23. doi: 10.1016/j.ajps.2020.06.001. Epub 2020 Jul 4.
SARS-CoV-2 has been marked as a highly pathogenic coronavirus of COVID-19 disease into the human population, causing over 5.5 million confirmed cases worldwide. As COVID-19 has posed a global threat with significant human casualties and severe economic losses, there is a pressing demand to further understand the current situation and develop rational strategies to contain the drastic spread of the virus. Although there are no specific antiviral therapies that have proven effective in randomized clinical trials, currently, the rapid detection technology along with several promising therapeutics for COVID-19 have mitigated its drastic transmission. Besides, global institutions and corporations have commenced to parse out effective vaccines for the prevention of COVID-19. Herein, the present review will give exhaustive details of extensive researches concerning the drug discovery and therapeutic options for COVID-19 as well as some insightful discussions of the status of COVID-19.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）已被标记为引发新冠肺炎疾病的高致病性冠状病毒，在全球范围内已造成超过550万例确诊病例。由于新冠肺炎对全球构成了威胁，造成了重大人员伤亡和严重经济损失，因此迫切需要进一步了解当前形势，并制定合理策略以遏制病毒的急剧传播。尽管尚无在随机临床试验中被证明有效的特异性抗病毒疗法，但目前，新冠肺炎的快速检测技术以及几种有前景的治疗方法已减缓了其急剧传播。此外，全球各机构和公司已开始研发预防新冠肺炎的有效疫苗。在此，本综述将详细阐述关于新冠肺炎药物研发和治疗选择的广泛研究，以及对新冠肺炎现状的一些深刻讨论。
